Recursion Pharmaceuticals Inc (NASDAQ: RXRX) open the trading on Wednesday, with great promise as it jumped 11.43% to $4.68, before settling in for the price of $4.2 at the close. Taking a more long-term approach, RXRX posted a 52-week range of $3.79-$12.36.
The Healthcare sector firm’s twelve-monthly sales growth has been -35.28% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -35.28%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 6.97%. This publicly-traded company’s shares outstanding now amounts to $485.21 million, simultaneously with a float of $431.60 million. The organization now has a market capitalization sitting at $2.44 billion. At the time of writing, stock’s 50-day Moving Average stood at $5.03, while the 200-day Moving Average is $5.19.
Recursion Pharmaceuticals Inc (RXRX) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Recursion Pharmaceuticals Inc’s current insider ownership accounts for 17.07%, in contrast to 48.82% institutional ownership. According to the most recent insider trade that took place on Dec 04 ’25, this organization’s Chief Executive Officer sold 40,000 shares at the rate of 4.63, making the entire transaction reach 185,200 in total value, affecting insider ownership by 933,839. Preceding that transaction, on Dec 02 ’25, Company’s Director sold 220,000 for 4.37, making the whole transaction’s value amount to 961,400. This particular insider is now the holder of 6,869,863 in total.
Recursion Pharmaceuticals Inc (RXRX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
Recursion Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 6.97% and is forecasted to reach -1.16 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 15.69% through the next 5 years, which can be compared against the -35.28% growth it accomplished over the previous five years trading on the market.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Let’s observe the current performance indicators for Recursion Pharmaceuticals Inc (RXRX). It’s Quick Ratio in the last reported quarter now stands at 4.60. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 55.75.
In the same vein, RXRX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.81, a figure that is expected to reach -0.31 in the next quarter, and analysts are predicting that it will be -1.16 at the market close of one year from today.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
[Recursion Pharmaceuticals Inc, RXRX] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 23.04% While, its Average True Range was 55.22.
Raw Stochastic average of Recursion Pharmaceuticals Inc (RXRX) in the period of the previous 100 days is set at 25.82%, which indicates a major fall in contrast to 56.85% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.29 that was lower than 0.35 volatility it exhibited in the past 100-days period.
